HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target
Connect Biopharma Holdings Ltd CNTB
$0.69
▼ -7.90%
($-0.06)
🧊 52W Low
⬇️ Below Yest. Low
📅 Earnings This Week
Open
$0.76
Prev Close
$0.75
Day Range
$0.68 – $0.76
52W Range
$0.71 – $3.82
Market Cap
$47.25M
Beta
-0.07
EPS (TTM)
$-1.20
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-03-19 |
| Shares Out. | 62,970,000 |
| Website | connectbiopharma.com ↗ |
| Phone | 18587271040 |
| Employees | 64 |
| Revenue | $2.8M |
| Gross Profit | $2.8M |
| Net Income | -$17.3M |
| Free Cash Flow | -$60.6M |
| Total Assets | $43.5M |
| Total Liabilities | $16.6M |
| Equity | $26.9M |
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
Connect Biopharma Holdings Ltd is a publicly traded company under the ticker symbol CNTB on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-11-01)